Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy, Rezdiffra (resmetirom), was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.
Role Overview:
Senior Manager, Publications
Reporting to the Senior Director, Publications, the Sr. Manager, Publications will be responsible for supporting the planning, coordination, and delivery of strategic peer-reviewed scientific materials. The Sr. Director, Publications will remain current on relevant medical/scientific therapeutic areas of interest to the company and professional standards to ensure they are able to provide timely, accurate, balanced and compliant peer-reviewed scientific publications.
Position Responsibilities:
- Support publications operational strategies/objectives for the Madrigal Pharmaceuticals product portfolio and/or products under clinical development
- Manage cross-functional publications team meetings
- Independently manage publications tracking system (PubStrat) and associated Madrigal publications repositories
- Provide quality review for publications (data checks, editing)
- Provide operational support for publications via literature search/evaluation, writing, management and review of publications deliverables (abstracts, posters, slide decks for presentation at congresses, manuscripts)
- Assist the Sr. Director, Publications in vendor selection, vetting, onboarding, troubleshooting
- Assist the Sr. Director, Publications in budget management and reporting
- Contribute to the development of Publications processes and SOPs
- Liaise with Medical Affairs (Medical Strategy and other Scientific Communications personnel) to identify emerging peer-reviewed publication content needs
- Follow the vision and strategy to enhance or create channels for communicating key scientific information about our products
Qualifications and Skills Required:
- Bachelor’s Degree in a scientific discipline, MS is preferred
- Minimum of 5+ years within the pharmaceutical industry; of which 3+ years of scientific publications management experience within the pharmaceutical industry, experience with submission of publications to scientific congresses and journals.
- Experience in medical writing and previous support of product launches preferred
- Demonstrated ability to work with cross functional teams is required.
- Well-developed project management and tracking skills; an understanding of drug development processes; basic understanding of statistical concepts related to reporting of scientific data.
- Ability to handle multiple demands in a fast-paced environment. Must be able to exercise appropriate judgment, as necessary. Requires a high level of initiative and independence. Organizational and planning skills, detail-oriented
- Experience in scientific/medical literature identification and evaluation
- Proficient in PC-based applications, including Microsoft SharePoint, Word, Excel, PowerPoint, and Outlook
- Proficient with publications tracking software (PubStrat)
- Up to 20% travel required
Compensation:
Base salary is determined by several factors that include, but are not limited to, a successful candidate's qualifications, skills, education, experience, business needs, and market demands. The role may also be eligible for bonus, equity, and comprehensive benefits, which include flexible paid time off (PTO), medical, dental, vision, and life and disability insurance.
Top Skills
What We Do
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com